1、Przemysl Chemiczny, 85(5), 349-350; 2006 2、Polymorphism of sodium valproate 【作 者】Mifsud, H.;Miguel, L.;Lavastre, V.;Maire, G. 【刊 名】Calorim. Anal. Therm. 【出版日期】1993 【卷 號】Vol.24 【頁 碼】309-312 3、Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC 4、[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group] 5、Ital J Gastroenterol. 1995 Sep;27(7):376-7. TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Leuschner U1, Guldutuna S, Bhatti S, Elze A, Imhof M, You T, Zimmer G. Author information 6、AJHYA2 American Journal of Hygiene. (Baltimore, MD) V.1-80, 1921-64. For publisher information, see AJEPAS. Volume(issue)/page/year: 76,209,1962   [更多]

文獻(xiàn)標(biāo)題 以及相關(guān)信息 1、舘田智昭ほか：薬理と治療、23(4)：833，1995 ウサギの実験的変形性関節(jié)癥 (OA) モデルおよび固定関節(jié)拘縮 (PS) モデルにおけるヒアルロン酸ナトリウム製剤 (ME3710) の薬効薬理試験 2、松井 裕ほか：薬理と治療、23(12)：3249，1995 ヒアルロン酸ナトリウム製剤(アダント^( !R))のビーグル犬における尿酸塩結(jié)晶誘発関節(jié)疼痛に対する抑制効果 3、基礎(chǔ)と臨床 29(6): 1357 -1383 1995 ME3710原末の毒性學(xué)的研究 (第1報(bào)) ―ラットの急性毒性及び亜急性毒性試験― 小林裕幸*1, 釜田悟*1, 八幡昭子*1, 常見邦順*1, 長谷淳一*1, 新保幸太郎*1, 井本精一*1, 鈴木平治郎*2 *1株式會社化合物安全性研究所, *2明治製菓株式會社薬品総合研究所 4、ME3710原末の毒性學(xué)的研究 (第2報(bào)) ―抗原性, 眼粘膜刺激性及び変異原性試験― 川初透*1, 井澤正典*1, 神藤康弘*1, 鎌田紘八*2, 小川明彥*2, 井上龍巳*2, 石原美加子*2, 磯和弘一*2, 今井順*2 *1明治製菓株式會社薬品総合研究所, *2株式會社日本生物化學(xué)センター岐阜研究所 基礎(chǔ)と臨床 29(6): 1385 -1396 1995 5、Gobert JG, Baltes EL. Availability and plasma clearance of piracetam in man. Farmaco 1977;3:84-91. 備注：將符合標(biāo)題的PDF上傳，先到先得   [更多]

標(biāo)題：求海關(guān)進(jìn)出口數(shù)據(jù)8位或者10位碼對應(yīng)的具體商品 具體要求：求海關(guān)進(jìn)出口數(shù)據(jù)稅則10位碼對應(yīng)的具體商品，只要海關(guān)稅則第二十九章 有機(jī)化合物，第三十章 藥品； 比如：2941.4000 -氯霉素及其衍生物以及它們的鹽，具體品種則包含氟苯尼考、氟苯尼考FLORFENICOL、合霉素DL-CHLORAMPHENICOL、合霉素、氯霉素堿、氟苯尼考、氯霉素等等品種。 具體要求也可以參照附件的格式，如果您平時(shí)有用到海關(guān)數(shù)據(jù)，還請您分享一下！   [更多]

需要江西省所有醫(yī)院的等級，類型，床位數(shù)，地址等數(shù)據(jù)   [更多]

文獻(xiàn)標(biāo)題及其他信息如下： 1、Prediction of lyophile collapse temperature by dielectric analysis. 2、Immunotherapy with bestatin for acute non-lymphocytic leukemia (ANLL) in adults 3、Results of follow-up studies on prognosis after immunotherapy with bestatin in acute nonlymphocytic leukemia 4、Comparison of theeffects of tolvaptan and furosemide on renal water and sodium excretion inpatients with heart failure and advanced chronic kidney disease: a subanalysisof the K-STAR study 5、Survival Benefit ofTolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis 6、Protective Effectsof diuretics against development of cardiovascular disease in patients withchronic kidney disease: systematic review 備注：先到先得，提供PDF電子版   [更多]

文獻(xiàn)標(biāo)題及相關(guān)內(nèi)容 1、Temperature-sensitive liposomes for codelivery of tamoxifen and imatinib for synergistic breast cancer treatment（doi: 10.1080/08982104.2018.1502315） 2、 Hyaluronated Imatinib Liposomes with Hybrid approach to Target CD44 and P-gp Overexpressing MDR Cancer: An In-vitro, In-vivo and Mechanistic Investigation（doi: 10.1080/1061186X.2018.1497039） 3、Novel imatinib-loaded silver nanoparticles for enhanced apoptosis of human breast cancer MCF-7 cells. Artif Cells Nanomed Biotechnol（doi: 10.1080/21691401.2016.1202257） 4、Man-Fung Yuen, MD, PhD.Hepatocellular Carcinoma: A Global Perspective.2018 ASCO 5、CS-386の安全性試験実験動物に対する急性,亜急性ならびに慢性毒性試験(原著論文) 増?zhí)镌?(三共), 木村邦男 , 山下和男 , 金丸三記雄 , 松沼尚央 三共研究所年報(bào) (1341-741X)30巻 Page175-192(1978.12） 6、吉田 勇 ほか Jpn J Antibiot, 63(6),457-479,2010 備注：提供PDF原件電子檔，先到先得   [更多]

EP10.0: 1. 昔萘酸沙美特羅Salmeterol Xinafoate 2. 對氨基水楊酸鈉Sodium Aminosalicylate Dihydrate 3. 亞胺培南Imipenem monohydrate 4. 西司他丁鈉Cilastatin sodium 5. 制霉菌素Nystatin 6. ω-3 脂肪酸甘油三酯Omega-3-Acid Triglycerides 7. 噻托溴銨一水合物Tiotropium Bromide Monohydrate 8. 硫酸沙丁胺醇Sulbutamol Sulphate 文獻(xiàn)： 1、Preventative approaches for neurophathy in diabetes with Alpha-lipoic Acid 2奧硝哩 在人體 內(nèi)的代謝與排泄研究 杜江 波 ” , 尤 天庚 ’ , 陳笑艷 ’ , 鐘 大放 ” 1. 中國科學(xué)院上海藥物研究所 , 上海 2 0 1 2 03 2 . 上海東方醫(yī)院 , 上海 2 0 01 2 0   [更多]

1.Myopia Control with Bifocal Contact Lenses:?A Randomized Clinical Trial 2.The Role of Atropine Eye Drops in Myopia Control 4. Myopia Control: A Review 7. Efficacy of 1%?atropine?eye drops in retarding progressive axial myopia in Indian eyes 8.Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia 9.Current approaches to myopia control 10.Atropine?for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines 13. Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. 18. The treatment of myopia with?atropine?and bifocals. A long-term prospective study 19. Inhibitory effects of apomorphine and?atropine?and their combination on myopia in chicks 20. The penetration and distribution of topical?atropine?in animal ocular tissues. 21. Treatment outcomes of?myopic?anisometropia with 1%?atropine: a pilot study 23. Does?atropine?use increase intraocular pressure in?myopic?children? 24. Atropine?use for the prevention of myopia progression 25. Allergic reactions to?atropine?eye drops for retardation of progressive myopia in children. 29. Maximum?atropine?dose without clinical signs or symptoms. 31. Atropine?and bifocals can slow the progression of myopia in children. 33. Prevention of myopia onset with 0.025%?atropine?in premyopic children 35. The long-term results of using low-concentration?atropine?eye drops for controlling myopia progression in schoolchildren. 37. Prevention of myopia progression with 0.05%?atropine?solution.   [更多]

1、American Conference of Governmental Industrial Hygienists TLVs and BEIs. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH, 2008, 2、內(nèi)容：Totsuka K，F(xiàn)urukawa M，F(xiàn)uruya N，et al. PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial （3）.45th Intersci Conf Antimicrob Agents Chemother（ICAAC）（Dec 16-19. Washington，D.C.），2005，Abst L-579標(biāo)題 PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial； 3、PK–PD analysis of tebipenem pivoxil in clinical trials for pediatric patients. Jpn J Chemother. 2009;57(S-1):186–91. 4、Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. González MA1, Straughan AB. 5、Single dose study of the bioequivalence of two sustained-release theophylline formulations. Contreras J, Pérez N, González R, Ontivero E, López M. Arzneimittelforschung. 1998 Mar;48(3):259-62. 6、National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information., AD277-689 7、Graul, A.; Castaner, J.; Atorvastatin Calcium. Drugs Fut 1997, 22, 9, 956. 8、Formulation And Evaluation of Topical Aceclofenac Gel Using Different Gelling Agent（JAPAN PATEL1*, BRIJESH PATEL1, HARDEEPSINGH BANWAIT1, KAUSHAL PARMAR1,MANISH PATEL2 Department of Pharmaceutics, Sat Kaival College of Pharmacy, Sarsa, Anand, Gujarat, India Nootan Pharmacy College, Visnagar, Gujarat, India） 9、NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec;10(12):1813-22 10、Preliminary studies on toxic effects of some vulcanizing accelerators 11、Dose Dumping Dose dumping is an increased concern with drugs manufactured as modified-release (MR) formulations, that is, where drug   [更多]

因涉及保密工作，請有意的個(gè)人私聊，不提倡團(tuán)隊(duì)接這個(gè)任務(wù)。   [更多]